European Pharmaceutical Review

DECEMBER 11, 2023

The findings were presented at the 2023 American Society of Hematology (ASH) Annual Meeting. For the patients treated with the microbiome therapeutic, overall survival was 81 percent for responders and eight percent for non-responders, in population matching patients in the ongoing Phase III ARES clinical trial.

Hospitals 116

Hospitals 116

PharmaTech

JANUARY 4, 2024

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

52

52

Express Pharma

JANUARY 30, 2024

Glenmark Pharmaceuticals and Ichnos Sciences, its global fully integrated, clinical-stage biotech subsidiary, announced the launch of their alliance – Ichnos Glenmark Innovation – to accelerate new drug discovery in cancer treatment. Two of these molecules have received orphan drug designation from the US FDA.

97

97

Pharmaceutical Commerce

FEBRUARY 8, 2024

The FDA placed a full clinical hold on magrolimab for hematologic cancers after data showed the drug in combination with azacitidine plus Venclexta increased the risk of death related to infections and respiratory failure in patients with acute myeloid leukemia.

52

52

Express Pharma

MAY 17, 2023

Immuno-oncology (IO) agents have transformed the oncology landscape in the last decade, particularly immune checkpoint inhibitors (ICIs) in solid tumor settings and chimeric antigen receptor (CAR) T-cells in hematological malignancies, with patients who previously had very limited therapeutic options achieving long term remissions and even cure.

Immunity 91

Immunity Immunization Vaccines 91

Express Pharma

MARCH 21, 2024

Biswajit Podder, Oncology and Hematology Analyst at GlobalData, comments, “Braftovi, in combination with Eli Lilly’s Erbitux (cetuximab), is used for patients with metastatic colorectal cancer harboring the BRAF V600E mutation.

93

93

Pharmafile

DECEMBER 11, 2023

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful and durable response in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).

59

59

PharmaShots

MARCH 16, 2023

Shots: The companies collaborated to evaluate PRT2527 (CDK9 inhibitor) + zanubrutinib (BTK inhibitor) in patients with hematologic malignancies. PRT2527 is being studied as monotx.

40

40

Express Pharma

APRIL 25, 2024

Biswajit Podder, Oncology and Hematology Analyst at GlobalData, comments, “Amidst this progress, AstraZeneca and Merck voluntarily withdrew approval for Lynparza in BRCA-mutated advanced ovarian cancer patients who have received at least three prior lines of chemotherapy. billion in sales and 28 per cent of the market share.

Chemotherapy 115

Chemotherapy 115

World Pharma News

MAY 22, 2023

Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that the company has nominated a potentially best-in-class preclinical candidate targeting ENPP1 for cancer immunotherapy and the potential treatment of Hypophosphatasia (HPP).

Immunity 64

Immunity Immunization 64

Outsourcing Pharma

MARCH 21, 2023

Non-clinical research has been published about roginolisob, iOncturaâs non-ATP competitive alloseteric modulator of PI3KÎ, for the potential treatment of patients with solid and hematological tumors.

52

52

European Pharmaceutical Review

DECEMBER 6, 2023

Over one-third of those patients require blood transfusions at least once per year, according to research published in a 2017 paper in Blood and a 2022 paper in Annals of Hematology. Approval of iptacopan for the aforementioned indication is based on two Phase III studies.

88

88

Pharmaceutical Technology

DECEMBER 25, 2023

PRGN-3007 is under clinical development by Precigen and currently in Phase I for Hematological Tumor.

52

52

Board Vitals - Pharmacist

JANUARY 24, 2024

Hematology The Hematology board exam saw a slight increase in pass rates, going from 90% in 2022 to 92% in 2023. Success in the exams is contingent on a comprehensive understanding of the material, critical thinking skills, and the ability to apply knowledge in diverse clinical scenarios. Don’t become complacent.

101

101

Pharmaceutical Business Review

FEBRUARY 12, 2024

This designation is a significant milestone for the company as it aims to develop treatments for rare hematologic conditions. Subsequently, the company initiated a Phase I clinical trial of DISC-3405 in healthy volunteers in October, with the goal of eventually treating not only PV but also other hematologic conditions.

59

59

Pharmaceutical Technology

AUGUST 4, 2022

Poseida Therapeutics and Roche have signed a strategic partnership and licence agreement to develop allogeneic CAR-T cell therapies for hematologic malignancies. P-BCMA-ALLO1 is currently being analysed in a Phase I clinical trial while an investigational new drug (IND) application for P-CD19CD20-ALLO1 is anticipated next year.

59

59

Pharmacy Times

SEPTEMBER 30, 2022

The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.

26

26

Pharmaceutical Technology

MARCH 28, 2023

Multimillion collaboration marred by clinical data Cusatuzumab was previously studied in a multimillion-dollar collaboration between argenx and the Janssen Pharmaceuticals subsidiary Cilag International. Additionally, 10 patients experienced a complete remission (CR) with or without hematologic recovery. In the study, 45.5%

52

52

pharmaphorum

MAY 3, 2022

With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage.

Immunity 52

Immunity Immunization 52

ALiEM - Pharm Pearls

APRIL 10, 2023

All infants that present with concern for neonatal lupus erythematosus should have screening labs performed to evaluate for hematologic, cardiac, and hepatobiliary involvement including a CBC with differential, liver enzymes, and antibody testing. Neonatal lupus erythematosus: clinical findings and pathogenesis. 2004 Jan;9(1):52-6.

246

246

PharmaShots

FEBRUARY 17, 2023

Evorpacept is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain Ref: ALX Oncology | Image: ALX Oncology Related News:- UroGen Presents P-III (OLYMPUS) Trial Results of Jelmyto (mitomycin) for the Treatment of Low-Grade Upper Tract Urothelial Cancer at SUO 2022

40

40

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company offers generic medicines and biosimilars through Sandoz.

Generic Medicine 68

Generic Medicine Biosimilars Immunity Immunization 68

Pharmaceutical Business Review

MARCH 17, 2024

Bristol Myers Squibb Hematology, Oncology and Cell Therapy Late Clinical Development head and senior vice-president Anne Kerber said: “We are extremely pleased with the positive outcome of the ODAC meeting, which recognises the favourable benefit/risk profile of Abecma, and based on results from the KarMMa-3 study, we are confident in the significant (..)

59

59

PharmaTech

JULY 26, 2022

AstraZeneca's acquisition of TeneoTwo will give the company access to its clinical-stage T-cell engager, TNB-486, strengthening their hematological cancer pipeline.

40

40

European Pharmaceutical Review

OCTOBER 2, 2023

Commenting on the validation of the MAA, Dr John Scarlett, Geron’s Chairman and Chief Executive Officer declared: “Based on the clinical profile of imetelstat to date, we are optimistic about its potential to become a standard of care and address longstanding unmet needs of lower risk MDS patients.”

91

91

Express Pharma

NOVEMBER 20, 2023

The approval was based on a Phase II clinical trial as second-line therapy after prior asparaginase-based chemotherapy or chemo-radiotherapy for the treatment of adult patients with r/r ENKTL. There have also been observed hematologic and non-hematologic treatment-related toxicities during first-line therapy with asparaginase-based regimens.

Chemotherapy 91

Chemotherapy 91

Pharmaceutical Business Review

JANUARY 31, 2024

“We look forward to continuing our collaboration with FDA, as we explore the therapeutic benefits of combining NT-I7 with other anti-cancer treatments such as immunotherapies for patients with pancreatic cancer.” NT-I7 (efineptakin alfa) is claimed to be the only clinical-stage long-acting human IL-7.

Immunity 59

Immunity Immunization Vaccines 59

Pharmacy Times

JANUARY 13, 2023

Developments may soon impact clinical practice in hematology and oncology.

49

49

Pharmaceutical Business Review

JANUARY 31, 2024

“We look forward to continuing our collaboration with FDA, as we explore the therapeutic benefits of combining NT-I7 with other anti-cancer treatments such as immunotherapies for patients with pancreatic cancer.” NT-I7 (efineptakin alfa) is claimed to be the only clinical-stage long-acting human IL-7.

Immunity 52

Immunity Immunization Vaccines 52

European Pharmaceutical Review

SEPTEMBER 1, 2023

mRNA stability and delivery specificity are two of the main obstacles hindering progress for oncology therapy approvals, according to Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData. Additionally, there are 178 mRNA-based oncology therapies in total across all clinical stages of development. subvariant. subvariant.

Immunity 94

Immunity Immunization Vaccines 94

European Pharmaceutical Review

DECEMBER 5, 2023

The promise of telomerase inhibitors for treating blood cancer Trial results The clinical trial enrolled a total of 178 patients. Significant and clinically meaningful efficacy results were achieved across key MDS subgroups irrespective of ring sideroblast (RS) status, baseline transfusion burden and IPSS risk category.

Hospitals 100

Hospitals 100

Pharmaceutical Technology

NOVEMBER 22, 2022

The robust expertise of IASO in monitoring possibly best-in-class CARs leveraging its fully-human antibody discovery platform (IMARS), quickly conducting clinical trials and its in-house GMP facility for producing plasmid, virus vector and CAR-T cells intends to make its new therapies available to larger population across the world.

110

110

European Pharmaceutical Review

DECEMBER 5, 2022

MOMENTUM was a randomised, double-blind Phase III clinical trial of momelotinib versus danazol in symptomatic and anaemic myelofibrosis patients treated with a US Food and Drug Administration (FDA)-approved JAK inhibitor. The Phase III trial for momelotinib. Further developments for the myelofibrosis treatment.

80

80

Express Pharma

AUGUST 31, 2023

BioNTech’s diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials, predominantly targeting solid tumors such as melanoma, prostate cancer, cervical cancer, non-small cell lung cancer, and pancreatic cancer. The technology bears tremendous promise, particularly for difficult-to-treat solid tumors.

Immunity 104

Immunity Immunization Vaccines 104

Pharmafile

JANUARY 5, 2023

Published date: 05/01/2023. read more.

40

40

PharmaShots

MAY 30, 2023

analytical, in vitro non-clinical data, and clinical data. The P-III study showed an equivalent clinical efficacy of Epysqli (first approved hematology biosimilar) over eculizumab after evaluating LDH in PNH patients Additionally, the company has seven biosimilars approved for use in the EU incl.

Biosimilars 40

Biosimilars 40

European Pharmaceutical Review

MARCH 14, 2023

Pfizer stated the intended combination with Seagen would double its early-stage oncology clinical pipeline. Its portfolio includes four approved medicines that are first- or best-in-class across solid tumours and hematologic malignancies.

110

110